Skip to Main Content
Phase III

Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (MAPLE)

  • Study HIC#:2000034724
  • Last Updated:11/29/2023

Obstructive HCM (oHCM) is an inherited condition in which the abnormally thickened heart muscles can block blood flow out of the heart to the body. This obstruction causes the heart muscle to work harder to pump blood to the body and can cause chest pain, dizziness, shortness of breath, and fainting. HCM is the most common inherited cardiovascular disorder, affecting approximately 1 in 500 individuals worldwide.

The purpose of this study is to compare the safety and effectiveness of aficamten with the beta-blocker, metoprolol, in participants with obstructive hypertrophic cardiomyopathy (oHCM). The effectiveness of both medicines will be compared by measuring your ability to exercise, day-to-day symptoms, and the structure of your heart by taking an echocardiogram (pictures of your heart taken outside your body). Participants will be randomly assigned to receive either metoprolol or aficamten.

There is no cost to participate in the study. If you qualify, the investigational drug, study-related tests, assessments, and study visits will be provided at no cost. Volunteers who qualify to take part in the study may receive compensation for study related travel expenses.

  • Age18 years - 85 years
  • GenderBoth

Contact Us

For more information about this study, including how to volunteer, contact:

Robert Cantafio

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.

Trial Purpose and Description

Obstructive HCM (oHCM) is an inherited condition in which the abnormally thickened heart muscles can block blood flow out of the heart to the body. This obstruction causes the heart muscle to work harder to pump blood to the body and can cause chest pain, dizziness, shortness of breath, and fainting. HCM is the most common inherited cardiovascular disorder, affecting approximately 1 in 500 individuals worldwide.

The purpose of this study is to compare the safety and effectiveness of aficamten with the beta-blocker, metoprolol, in participants with obstructive hypertrophic cardiomyopathy (oHCM). The effectiveness of both medicines will be compared by measuring your ability to exercise, day-to-day symptoms, and the structure of your heart by taking an echocardiogram (pictures of your heart taken outside your body). Participants will be randomly assigned to receive either metoprolol or aficamten.

There is no cost to participate in the study. If you qualify, the investigational drug, study-related tests, assessments, and study visits will be provided at no cost. Volunteers who qualify to take part in the study may receive compensation for study related travel expenses.

Eligibility Criteria

You may qualify:

  • If you have been diagnosed with oHCM.
  • If you are between the ages of 18 and 85.
  • If you still have symptoms related to your heart condition even though you are on certain medications.
  • Regardless of whether or not you have received medication for your oHCM, such as beta-blockers or calcium channel blockers. Ask your doctor for more information.
  • Additional eligibility criteria may need to be met to qualify for the study.

For more information about this study, including how to volunteer, contact: